Imagion Biosystems Ltd (IBX) - Total Liabilities

Latest as of June 2025: AU$4.80 Million AUD ≈ $3.40 Million USD

Based on the latest financial reports, Imagion Biosystems Ltd (IBX) has total liabilities worth AU$4.80 Million AUD (≈ $3.40 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore how efficiently does Imagion Biosystems Ltd generate cash to assess how effectively this company generates cash.

Imagion Biosystems Ltd - Total Liabilities Trend (2014–2024)

This chart illustrates how Imagion Biosystems Ltd's total liabilities have evolved over time, based on quarterly financial data. Check Imagion Biosystems Ltd (IBX) liquid assets ratio to evaluate the company's liquid asset resilience ratio.

Imagion Biosystems Ltd Competitors by Total Liabilities

The table below lists competitors of Imagion Biosystems Ltd ranked by their total liabilities.

Company Country Total Liabilities
Viji Finance Limited
NSE:VIJIFIN
India Rs134.80 Million
THG Holdings PLC
LSE:THG
UK GBX1.20 Billion
CU Medical Systems Inc
KQ:115480
Korea ₩42.18 Billion
Eko Export SA
WAR:EEX
Poland zł44.67 Million
Macarthur Minerals Ltd
AU:MIO
Australia AU$1.32 Million
Enlitic Inc
AU:ENL
Australia AU$4.24 Million
KWANGJIN WINTEC CO. Ltd
KQ:090150
Korea ₩81.45 Billion

Liability Composition Analysis (2014–2024)

This chart breaks down Imagion Biosystems Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see IBX company net worth.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 0.19 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity -1.24 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 5.15 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Imagion Biosystems Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Imagion Biosystems Ltd (2014–2024)

The table below shows the annual total liabilities of Imagion Biosystems Ltd from 2014 to 2024.

Year Total Liabilities Change
2024-12-31 AU$5.09 Million
≈ $3.60 Million
-39.26%
2023-12-31 AU$8.37 Million
≈ $5.93 Million
+58.06%
2022-12-31 AU$5.30 Million
≈ $3.75 Million
+554.19%
2021-12-31 AU$809.88K
≈ $573.04K
-32.80%
2020-12-31 AU$1.21 Million
≈ $852.71K
-36.52%
2019-12-31 AU$1.90 Million
≈ $1.34 Million
+44.02%
2018-12-31 AU$1.32 Million
≈ $932.73K
+91.39%
2017-12-31 AU$688.77K
≈ $487.35K
+52.39%
2016-12-31 AU$451.99K
≈ $319.81K
-95.32%
2015-12-31 AU$9.65 Million
≈ $6.83 Million
+123.93%
2014-12-31 AU$4.31 Million
≈ $3.05 Million
--

About Imagion Biosystems Ltd

AU:IBX Australia Diagnostics & Research
Market Cap
$5.90 Million
AU$8.34 Million AUD
Market Cap Rank
#28035 Global
#1515 in Australia
Share Price
AU$0.02
Change (1 day)
+21.43%
52-Week Range
AU$0.01 - AU$0.05
All Time High
AU$8.60
About

Imagion Biosystems Limited provides medical imaging technologies using magnetic resonance. It is involved in the nanotechnology; biotechnology; and cancer diagnostics businesses. The company develops MagSense, which completed Phase 1 for the treatment of HER2 breast cancers, as well as advancing the research and development programs for prostate and ovarian cancer. It also develops PrecisionMRX, … Read more